Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)
- 113 Downloads
The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).
Patients and methods
We retrospectively analyzed 30 cases fulfilling the criteria of PTCL-U defined by the World Health Organization classification. The patients were treated with 6–8 cycles of a CHOP or THP (pirarubicin)-COP regimen.
A high serum sIL-2R level (≥2,000 U/ml) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5 year, 15.1%) than those with low sIL-2R (<2,000 U/ml) (100%) (P < 0.005). Factors associated with worse overall survival in a univariate analysis were high sIL-2R (P < 0.005), high age (>60 years) (P < 0.05), poor performance status (P < 0.01) and poor international prognostic index (P < 0.05). No correlation was observed between sIL-2R and other markers. Multivariate analysis showed that only sIL-2R was a prognostic factor for overall survival (P < 0.01).
The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U.
KeywordsPeripheral T-cell lymphoma (PTCL) Soluble interleukin-2 receptor (sIL-2R) Prognostic analysis
- Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M (2004) Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–2479. doi: 10.1182/blood-2003-09-3080 PubMedCrossRefGoogle Scholar
- Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M et al (2005) Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 131:73–79. doi: 10.1007/s00432-004-0600-9 PubMedCrossRefGoogle Scholar
- Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S et al (2006) Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. Eur J Haematol 77:217–225. doi: 10.1111/j.1600-0609.2006.00702.x PubMedCrossRefGoogle Scholar
- Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P et al (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87–2. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 15:1131–1137PubMedGoogle Scholar
- Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849PubMedGoogle Scholar
- Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K et al (1996) Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. Br J Haematol 93:45–52. doi: 10.1046/j.1365-2141.1996.4641003.x PubMedCrossRefGoogle Scholar
- Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H et al (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354–361. doi: 10.1034/j.1600-0609.2002.01654.x PubMedCrossRefGoogle Scholar
- Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y et al (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107–113. doi: 10.1007/s00432-003-0508-9 PubMedCrossRefGoogle Scholar
- Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M et al (1996) Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 132:42–47. doi: 10.1001/archderm.132.1.42 PubMedCrossRefGoogle Scholar